Literature DB >> 16675851

Enhanced expression of hypersensitive alpha4* nAChR in adult mice increases the loss of midbrain dopaminergic neurons.

Johannes Schwarz1, Sigrid C Schwarz, Oliver Dorigo, Alexandra Stützer, Florian Wegner, Cesar Labarca, Purnima Deshpande, Jose S Gil, Arnold J Berk, Henry A Lester.   

Abstract

We describe an inducible genetic model for degeneration of midbrain dopaminergic neurons in adults. In previous studies, knock-in mice expressing hypersensitive M2 domain Leu9'Ser (L9'S) alpha4 nicotinic receptors (nAChR) at near-normal levels displayed dominant neonatal lethality and dopaminergic deficits in embryonic midbrain, because the hypersensitive nAChR is excitotoxic. However, heterozygous L9'S mice that retain the neomycin resistance cassette (neo) in a neighboring intron express low levels of the mutant allele (approximately 25% of normal levels), and these neo-intact mice are therefore viable and fertile. The neo cassette is flanked by loxP sites. In adult animals, we locally injected helper-dependent adenovirus (HDA) expressing cre recombinase. Local excision of the neo cassette, via cre-mediated recombination, was verified by genomic analysis. In L9'S HDA-cre injected animals, locomotion was reduced both under baseline conditions and after amphetamine application. There was no effect in L9'S HDA-control treated animals or in wild-type (WT) littermates injected with either virus. Immunocytochemical analyses revealed marked losses (> 70%) of dopaminergic neurons in L9'S HDA-cre injected mice compared to controls. At 20-33 days postinjection in control animals, the coexpressed marker gene, yellow fluorescent protein (YFP), was expressed in many neurons and few glial cells near the injection, emphasizing the neurotropic utility of the HDA. Thus, HDA-mediated gene transfer into adult midbrain induced sufficient functional expression of cre in dopaminergic neurons to allow for postnatal deletion of neo. This produced increased L9'S mutant nAChR expression, which in turn led to nicotinic cholinergic excitotoxicity in dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675851     DOI: 10.1096/fj.05-5497com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

1.  High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.

Authors:  Zhicheng Lin; Ying Zhao; Chee Yeun Chung; Yanhong Zhou; Nian Xiong; Charles E Glatt; Ole Isacson
Journal:  FASEB J       Date:  2010-02-24       Impact factor: 5.191

Review 2.  Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses.

Authors:  Julie M Miwa; Robert Freedman; Henry A Lester
Journal:  Neuron       Date:  2011-04-14       Impact factor: 17.173

Review 3.  Recent advances in gene manipulation and nicotinic acetylcholine receptor biology.

Authors:  Anne Tammimäki; William J Horton; Jerry A Stitzel
Journal:  Biochem Pharmacol       Date:  2011-06-16       Impact factor: 5.858

Review 4.  Insights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutations.

Authors:  Ryan M Drenan; Henry A Lester
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

Review 5.  Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction.

Authors:  Yann S Mineur; Marina R Picciotto
Journal:  Biochem Pharmacol       Date:  2007-06-14       Impact factor: 5.858

6.  Characterization of de novo synthesized GPCRs supported in nanolipoprotein discs.

Authors:  Tingjuan Gao; Jitka Petrlova; Wei He; Thomas Huser; Wieslaw Kudlick; John Voss; Matthew A Coleman
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

7.  Chronic-Progressive Dopaminergic Deficiency Does Not Induce Midbrain Neurogenesis.

Authors:  Mareike Fauser; Francisco Pan-Montojo; Christian Richter; Philipp J Kahle; Sigrid C Schwarz; Johannes Schwarz; Alexander Storch; Andreas Hermann
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.